Immunoglobulin E (IgE) specific for ash pollen allergens (Ash-specific IgE)

IgE antibodies specific for ash pollen allergens are a specialized class of immunoglobulins that mediate Type I hypersensitivity reactions to pollen from trees in the Fraxinus genus, primarily Fraxinus excelsior (European ash) (ThermoFisher, 2022). These antibodies are produced by B cells following sensitization to specific ash pollen proteins, most notably the major allergen Fra e 1, which shares high homology with the olive allergen Ole e 1 (NIH, 2014; ResearchGate, 2002). In sensitized individuals, these IgE molecules bind to high-affinity FcεRI receptors on the surface of mast cells and basophils (NIH, 2021). Upon re-exposure to ash pollen, the allergens cross-link the receptor-bound IgE, triggering the rapid degranulation of these effector cells and the release of inflammatory mediators such as histamine and leukotrienes (NIH, 2021; Drugs.com, 2025). This inflammatory cascade leads to clinical symptoms of allergic rhinitis, conjunctivitis, and asthma (ThermoFisher, 2022; NIH, 2006). Therapeutic strategies targeting this pathway include the use of anti-IgE monoclonal antibodies like omalizumab, which sequester free IgE and prevent its interaction with cellular receptors (NIH, 2021; ResearchGate, 2024). Additionally, allergen-specific immunotherapy (AIT) is employed to induce immune tolerance, often characterized by a shift from IgE-mediated responses to the production of protective IgG4 blocking antibodies (NIH, 2021; AAAAI, 2021). Monitoring the levels of these specific IgE antibodies through serum assays or skin prick tests is essential for the diagnosis of ash pollinosis and for evaluating the efficacy of immunotherapeutic interventions (NIH, 2021; ThermoFisher, 2022).

Other names

Fraxinus excelsior specific IgEAsh pollen-specific IgEAnti-ash pollen IgEFra e 1 specific IgEFra e 2 specific IgEFra e 3 specific IgE

Anti-IgE monoclonal antibodies like omalizumab bind to the Fc region (specifically the Cε3 domain) of free IgE in the circulation, preventing its interaction with high-affinity IgE receptors (FcεRI) on mast cells and basophils. This sequestration reduces the density of IgE on the cell surface, leads to the downregulation of FcεRI expression, and inhibits the release of inflammatory mediators (NIH, 2021; ResearchGate, 2024). Allergen-specific immunotherapy (AIT) works by inducing immune tolerance through the modulation of T-cell responses (shifting from Th2 to Th1/Treg), which promotes the production of allergen-specific IgG4 blocking antibodies. These IgG4 antibodies compete with IgE for allergen binding, thereby preventing the cross-linking of IgE on effector cells and suppressing the allergic response (NIH, 2021; AAAAI, 2021).